CCL14, identified by multi-omics approach, serves as a novel indicator of disease severity and progression in lymphangioleiomyomatosis.

Critically, CCL14 predicted disease progression: baseline CCL14 levels were higher in progressive versus stable patients (p = 0.0266) and positively correlated with annual increase in the percentage of cystic lung volume (r = 0.4051, p = 0.0446).

Countstar Rigel S2 supported assessment of nuclei numbers in the study's cell samples before single-cell analysis in the 2026 Orphanet journal of rare diseases study.